Newron Pharmaceuticals notes new publication highlighting clinically meaningful benefits of evenamide as an adjunctive treatment in schizophrenia ...
Rithm Capital Corp. (NYSE: RITM; "Rithm Capital," "Rithm" or the "Company") today reported the following information for the fourth quarter ended and full year ended December 31, 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results